1. Aprotinin use in thoracic aortic surgery: Safety and outcomes
- Author
-
Sedrakyan, Artyom, Wu, Albert, Sedrakyan, George, Diener-West, Marie, Tranquilli, Maryann, and Elefteriades, John
- Subjects
Surgery -- Analysis ,Surgery -- Safety and security measures ,Health - Abstract
To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.jtcvs.2006.06.021 Byline: Artyom Sedrakyan (a)(b), Albert Wu (b)(c), George Sedrakyan (d), Marie Diener-West (e), Maryann Tranquilli (a), John Elefteriades (a) Abbreviations: ACT, activated clotting time; CABG, coronary artery bypass graft; ECM, extracellular matrix; DHCA, deep hypothermic cardiac arrest; KIU, kallikrein inactivation unit Abstract: Previous studies of aprotinin use in thoracic aortic surgery, limited in size and design, reported minimal information regarding outcomes other than blood loss and transfusion. The evaluation of impact of aprotinin on surgical outcomes in a large sample is needed. Author Affiliation: (a) Department of Surgery, Yale University School of Medicine, New Haven, Conn (b) Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Md (c) Health Services Research and Development Center, Johns Hopkins University, Baltimore, Md (d) Nork-Marash Cardiac Surgery Hospital, Yerevan, Armenia (e) Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Md. Article History: Received 1 November 2005; Accepted 6 June 2006 Article Note: (footnote) The chart review, data collection, and data analysis conducted in this study were supported by an investigator-initiated proposal and subsequent phase IV funding by Bayer Pharmaceuticals Corporation, West Haven, Conn, the manufacturer of aprotinin. Artyom Sedrakyan and John Elefteriades report lecture fees and grant support from Bayer Pharmaceuticals Corporation.
- Published
- 2006